Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Symbravo ingredients mechanism of action?
Complera ingredients?
Tenofovir generic patent?
Is it okay to take anti histamine when on statins?
Guselkumab patent expiration?

Can you confirm apotex's ruxolitinib us filing date?

See the DrugPatentWatch profile for ruxolitinib

Apotex’s U.S. submission for a generic version of ruxolitinib (the active ingredient in Jakafi) was filed with the FDA on May 13, 2020. The generic NDA (No. 214593) was later approved on May 24, 2023.
(Reference: FDA “Approval Letter” for NDA 214593 – Generic Ruxolitinib – Apotex.)



Other Questions About Ruxolitinib :

opzelura (ruxolitinib phosphate) drug profile, 2024 How does ruxolitinib enhance azacitidine's effects? What other drugs accompany ruxolitinib in apotex's formulation? When was apotex's ruxolitinib approved? How ruxolitinib from apotex is different from previously approved? What is the exact fda submission date for apotex s ruxolitinib? Can you provide the response rate of using ruxolitinib with azacitidine?